A lack of effect of captopril on platelet aggregation in patients with congestive heart failure

• Published in: European journal of clinical pharmacology Vol. 41; no. 1; pp. 47 - 49
• Main Authors: GOW, I. F, FLAPAN, A. D, MORRIS, M, DAVIES, E, WILLIAMS, B. C, PADFIELD, P. L, SHAW, T. R. D, EDWARDS, C. R. W
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01-01-1991; Berlin
• Subjects: Angiotensin II - blood; Antihypertensive agents; Biological and medical sciences; Captopril - administration & dosage; Captopril - pharmacology; Cardiovascular system; Heart Failure - blood; Humans; Male; Medical sciences; Pharmacology. Drug treatments; Platelet Aggregation - drug effects; Renin - blood; Serotonin - blood; Aggregation; Human; Heart failure; Platelet; Serotonin; Enzyme; Angiotensin converting enzyme; Peptide hormone; Enzyme inhibitor; Antihypertensive agent; Cardiovascular disease; Angiotensin II
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/BF00280105

We have studied the acute and chronic effects of an ACE inhibitor (captopril) on platelet function and the renin-angiotensin system in patients with congestive heart failure. Plasma concentrations of angiotensin II fell significantly after a single dose of captopril (25 mg) and during long-term treatment with captopril (2 weeks, 75 mg/day). Plasma renin activity increased significantly after both the single and repeated doses. Captopril did not affect ADP-induced platelet aggregation or concentrations. It seems unlikely that circulating angiotensin II affects ADP-induced platelet aggregation in patients with congestive heart failure.